Premium
Farnesoid X receptor activation induces the degradation of hepatotoxic 1‐deoxysphingolipids in non‐alcoholic fatty liver disease
Author(s) -
Gai Zhibo,
Gui Ting,
Alecu Irina,
Lone Museer A.,
Hornemann Thorsten,
Chen Qingfa,
Visentin Michele,
Hiller Christian,
Hausler Stephanie,
KullakUblick Gerd A.
Publication year - 2020
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.14340
Subject(s) - farnesoid x receptor , fatty liver , apoptosis , medicine , endocrinology , cancer research , peroxisome proliferator activated receptor , alcoholic liver disease , chemistry , receptor , biology , nuclear receptor , biochemistry , disease , transcription factor , cirrhosis , gene
Background & Aims Patients with non‐alcoholic fatty liver disease (NAFLD) exhibit higher levels of plasma 1‐deoxysphingolipids than healthy individuals. The aim of this study was to investigate the role of farnesoid X receptor (FXR) in 1‐deoxysphingolipid de novo synthesis and degradation. Methods Mice were fed with a high‐fat diet (HFD) to induce obesity and NAFLD, and then treated with the FXR ligand obeticholic acid (OCA). Histology and gene expression analysis were performed on liver tissue. Sphingolipid patterns from NAFLD patients and mouse models were assessed by liquid chromatography‐mass spectrometry. The molecular mechanism underlying the effect of FXR activation on sphingolipid metabolism was studied in Huh7 cells and primary cultured hepatocytes, as well as in a 1‐deoxysphinganine‐treated mouse model. Results 1‐deoxysphingolipids were increased in both NAFLD patients and mouse models. FXR activation by OCA protected the liver against oxidative stress, apoptosis, and reduced 1‐deoxysphingolipid levels, both in a HFD‐induced mouse model of obesity and in 1‐deoxysphinganine‐treated mice. In vitro, FXR activation lowered intracellular 1‐deoxysphingolipid levels by inducing Cyp4f‐mediated degradation, but not by inhibiting de novo synthesis, thereby protecting hepatocytes against doxSA‐induced cytotoxicity, mitochondrial damage, and apoptosis. Overexpression of Cyp4f13 in cells was sufficient to ameliorate doxSA‐induced cytotoxicity. Treatment with the Cyp4f pan‐inhibitor HET0016 or FXR knock‐down fully abolished the protective effect of OCA, indicating that OCA‐mediated 1‐deoxysphingolipid degradation is FXR and Cyp4f dependent. Conclusions Our study identifies FXR‐Cyp4f as a novel regulatory pathway for 1‐deoxysphingolipid metabolism. FXR activation represents a promising therapeutic strategy for patients with metabolic syndrome and NAFLD.